US court denies injunction against Exubera
A US District Court for the Southern District of New York has rejected a motion for a preliminary injunction that would have blocked sales of Pfizer's inhalable insulin medication, Exubera, in the US.
The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court.
Exubera is the only inhalable form of insulin to be approved by the FDA. The court's decision allows the product to remain on the US market, and available to patients, while the case proceeds to trial.